公开(公告)号：US20140194486A1

公开(公告)日：2014-07-10

申请号：US14085632

申请日：2013-11-20

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Bernard Thomas GOLDING ,  Christiane Riedinger ,  Roger John Griffin ,  Ian Robert Hardcastle ,  Eric Valeur ,  Anna Frances Watson ,  Martin Noble

IPC: A61K31/4035 ,  C07D209/48

CPC classification number: C07D209/49 ,  A61K31/4035 ,  A61K31/4402 ,  A61K45/06 ,  C07D209/48 ,  C07D401/06 ,  C07D403/06

Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.

Abstract translation: 式（I）化合物或式（II）化合物或其药学上可接受的盐，其中R 1 -R 7和X如说明书中所定义，以及这些化合物在治疗中的用途，特别是在治疗癌症或作为 MDM2蛋白与p53相互作用的抑制剂。

公开(公告)号：US09358222B2

公开(公告)日：2016-06-07

申请号：US14085632

申请日：2013-11-20

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Bernard Thomas Golding ,  Christiane Riedinger ,  Roger John Griffin ,  Ian Robert Hardcastle ,  Eric Valeur ,  Anna Frances Watson ,  Martin Noble

IPC: C07D207/46 ,  A61K31/4035 ,  C07D209/48 ,  C07D401/06 ,  C07D403/06

CPC classification number: C07D209/49 ,  A61K31/4035 ,  A61K31/4402 ,  A61K45/06 ,  C07D209/48 ,  C07D401/06 ,  C07D403/06

Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.

公开(公告)号：US10414726B2

公开(公告)日：2019-09-17

申请号：US15715900

申请日：2017-09-26

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Bernard Thomas Golding ,  Christiane Riedinger ,  Roger John Griffin ,  Ian Robert Hardcastle ,  Eric Valeur ,  Anna Frances Watson ,  Martin Noble

IPC: C07D209/49 ,  C07D209/48 ,  C07D401/06 ,  C07D403/06 ,  A61K31/4035 ,  A61K31/4402 ,  A61K45/06

Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.